NEU.AX
Price:
$11.91
Market Cap:
$1.52B
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.[Read more]
Industry
Biotechnology
IPO Date
2005-02-01
Stock Exchange
ASX
Ticker
NEU.AX
According to Neuren Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current PE Ratio is 11.79. This represents a change of -63.83% compared to the average of 32.60 of the last 4 quarters.
The mean historical PE Ratio of Neuren Pharmaceuticals Limited over the last ten years is 546.78. The current 11.79 PE Ratio has changed 115.63% with respect to the historical average. Over the past ten years (40 quarters), NEU.AX's PE Ratio was at its highest in in the December 2021 quarter at 715.00. The PE Ratio was at its lowest in in the September 2009 quarter at -335.13.
Average
546.78
Median
-7.41
Minimum
-56.97
Maximum
5.44K
Discovering the peaks and valleys of Neuren Pharmaceuticals Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 279.20%
Maximum Annual PE Ratio = 5.44K
Minimum Annual Increase = -23484.53%
Minimum Annual PE Ratio = -56.97
Year | PE Ratio | Change |
---|---|---|
2023 | 20.08 | -99.63% |
2022 | 5.44K | -9654.01% |
2021 | -56.97 | 279.20% |
2020 | -15.02 | -34.59% |
2019 | -22.97 | -150.90% |
2018 | 45.12 | -51.11% |
2017 | 92.30 | -23484.53% |
2016 | -0.39 | -97.26% |
2015 | -14.42 | -35.76% |
2014 | -22.45 | 74.92% |
The current PE Ratio of Neuren Pharmaceuticals Limited (NEU.AX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.80K
5-year avg
1.07K
10-year avg
546.78
Neuren Pharmaceuticals Limited’s PE Ratio is less than Telix Pharmaceuticals Limited (256.90), less than Clinuvel Pharmaceuticals Limited (16.36), less than Antisense Therapeutics Limited (0), greater than Starpharma Holdings Limited (-5.50), greater than Pharmaxis Ltd (-2.15),
Company | PE Ratio | Market cap |
---|---|---|
256.90 | $8.03B | |
16.36 | $577.70M | |
0 | $52.29M | |
-5.50 | $45.99M | |
-2.15 | $20.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neuren Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neuren Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Neuren Pharmaceuticals Limited's PE Ratio?
How is the PE Ratio calculated for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the highest PE Ratio for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the 3-year average PE Ratio for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the 5-year average PE Ratio for Neuren Pharmaceuticals Limited (NEU.AX)?
How does the current PE Ratio for Neuren Pharmaceuticals Limited (NEU.AX) compare to its historical average?